Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase I Study of FT516 as Monotherapy in Relapsed/Refractory Acute Myelogenous Leukemia and in Combination With Monoclonal Antibodies in Relapsed/Refractory B-Cell Lymphoma

Trial Profile

A Phase I Study of FT516 as Monotherapy in Relapsed/Refractory Acute Myelogenous Leukemia and in Combination With Monoclonal Antibodies in Relapsed/Refractory B-Cell Lymphoma

Status: Recruiting
Phase of Trial: Phase I

Latest Information Update: 08 Dec 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs FT-516 (Primary) ; Cyclophosphamide; Dexamethasone; Elotuzumab; Fludarabine; Obinutuzumab; Pomalidomide; Rituximab
  • Indications Acute myeloid leukaemia; B-cell lymphoma; Haematological malignancies; Multiple myeloma; Non-Hodgkin's lymphoma
  • Focus Adverse reactions; First in man
  • Sponsors Fate Therapeutics
  • Most Recent Events

    • 08 Dec 2019 According to a Fate Therapeutics media release, first patient has been treated for acute myeloid leukemia in this study.
    • 03 Oct 2019 Status changed from not yet recruiting to recruiting.
    • 06 Aug 2019 According to a Fate Therapeutics media release, company is currently initiating clinical investigation of FT516 as a monotherapy for the treatment of acute myeloid leukemia and in combination with CD20-directed monoclonal antibodies for the treatment of B-cell lymphoma.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top